Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Neovasc Shares Climb 80% Upon FDA Premarket Approval Filing for Refractory Angina Device

Shares of specialty cardiovascular medical device company Neovasc Inc. opened more than 100% higher after the firm reported that it submitted a Premarket Approval application to the FDA for its Neovasc Reducer device for use in the treatment of refractory angina. This...
Streetwise Reports | January 3, 2020 |

The Medical Device Co. That’s on the Cutting-Edge of Advancing Heart Disease Treatment

Back in early September , we introduced our Stockhouse audience to a unique play in the emerging medical tech space – Neovasc Inc. ( TSX: NVCN , OTCQB: NVCN , Forum ). The company develops, manufactures, and markets products for the rapidly growing cardiovascular marke...
Dave Jackson | November 29, 2021 |

DIAGNOS poised for parabolic move as first of new cardio AI Applications comes to market

DIAGNOS Inc. (TSX-V: ADK) (OTCQB: DGNOF) (Frankfurt: 4D4) is a Canadian-based healthcare software technology company that pioneered ' C omputer A ssisted R etinal A nalysis' (CARA), applying artificial intelligence to non-invasively test, identify, and classify patients a...
James O'Rourke | May 5, 2020 |

Revolutionizing vascular grafting with a durable solution

Our next guest is a multi-technology biomedical company, focused on the development and commercialization of medical technologies. Marizyme Inc. (OTCQB:MRZM) has had its sights set on development of medical technology and products, one of which is DuraGraft. J...
Brieanna McCutcheon | September 27, 2023 |

Edwards Lifesciences Gets a Charge on Positive Q2 Earnings Report

Edwards Lifesciences is trading higher after reporting higher than expected adjusted earnings for Q2/19. The company estimates that the FDA will approve its SAPIEN 3 valve and SAPIEN 3 Ultra system in Q3/19. Structural heart disease and critical care monitor...
Streetwise Reports | July 25, 2019 |

Acceleron Shares Open 50% Higher on Phase 2 PAH Trial Data

Acceleron Pharma's shares established a new 52-week high after the company reported that sotatercept achieved both primary and secondary endpoints in the Phase 2 PULSAR study in patients with pulmonary arterial hypertension. After U.S. markets closed for trading ye...
Streetwise Reports | January 29, 2020 |

Kiniksa Shares Trade Up 30% on COVID-19 Pneumonia and Hyperinflammation Treatment

Shares of Kiniksa Pharmaceuticals traded higher after the company reported early success in treatment response for mavrilimumab in six patients with severe COVID-19 pneumonia and hyperinflammation. This morning, Hamilton, Bermuda based biopharmaceutical comp...
Streetwise Reports | April 1, 2020 |